Angela M Cheung1, Ruth Heisey, Jeevitha Srighanthan. 1. aWomen's Health Program bOsteoporosis Program cDepartment of Medicine dDepartment of Family and Community Medicine, University Health Network, University of Toronto, Ontario, Canada.
Abstract
PURPOSE OF REVIEW: Over the past few years, a number of studies have examined the relationship between breast cancer and osteoporosis, the effect of breast cancer treatment on bone health, and the effect of osteoporosis therapies on aromatase inhibitor-induced bone loss and breast cancer recurrence. New guidelines have been released on the prevention of osteoporotic fractures in women with breast cancer who are on aromatase inhibitors for adjuvant therapy. RECENT FINDINGS: Despite common factors linking high bone mineral density and increased risk of breast cancer, women with breast cancer are not protected from osteoporosis or osteoporotic fractures. Recent data suggest that aromatase inhibitors have a detrimental effect on bone mineral density and can increase the risk of fractures. Bisphosphonate therapy not only preserves aromatase inhibitor-induced bone loss, but may also improve disease-free survival and decrease risk of death in select women with breast cancer (i.e., postmenopausal women). SUMMARY: Osteoporosis and breast cancer are common in women, especially in postmenopausal women. Current guidelines suggest that we need to pay special attention to those on aromatase inhibitors to prevent adverse bone outcomes.
PURPOSE OF REVIEW: Over the past few years, a number of studies have examined the relationship between breast cancer and osteoporosis, the effect of breast cancer treatment on bone health, and the effect of osteoporosis therapies on aromatase inhibitor-induced bone loss and breast cancer recurrence. New guidelines have been released on the prevention of osteoporotic fractures in women with breast cancer who are on aromatase inhibitors for adjuvant therapy. RECENT FINDINGS: Despite common factors linking high bone mineral density and increased risk of breast cancer, women with breast cancer are not protected from osteoporosis or osteoporotic fractures. Recent data suggest that aromatase inhibitors have a detrimental effect on bone mineral density and can increase the risk of fractures. Bisphosphonate therapy not only preserves aromatase inhibitor-induced bone loss, but may also improve disease-free survival and decrease risk of death in select women with breast cancer (i.e., postmenopausal women). SUMMARY:Osteoporosis and breast cancer are common in women, especially in postmenopausal women. Current guidelines suggest that we need to pay special attention to those on aromatase inhibitors to prevent adverse bone outcomes.
Authors: Adetunji T Toriola; Jingxia Liu; Patricia A Ganz; Graham A Colditz; Lin Yang; Sonya Izadi; Michael J Naughton; Anna L Schwartz; Kathleen Y Wolin Journal: Breast Cancer Res Treat Date: 2015-07-15 Impact factor: 4.872
Authors: Thomas Baum; Dimitrios C Karampinos; Vanadin Seifert-Klauss; Tsvetelina D Pencheva; Pia M Jungmann; Ernst J Rummeny; Dirk Müller; Jan S Bauer Journal: Clin Cases Miner Bone Metab Date: 2016-05-11
Authors: Alessandro de Sire; Lorenzo Lippi; Konstantinos Venetis; Stefania Morganti; Elham Sajjadi; Claudio Curci; Antonio Ammendolia; Carmen Criscitiello; Nicola Fusco; Marco Invernizzi Journal: Front Oncol Date: 2022-01-21 Impact factor: 6.244